Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients

Jordan K. Schaefer, Robert D. McBane, David F. Black, Lindsy N. Williams, Kevin G. Moder, Waldemar E. Wysokinski

Research output: Contribution to journalArticle

71 Scopus citations

Abstract

Direct oral factor inhibitors (DOFIs) are an attractive alternative to vitamin K antagonists (VKA) for the treatment of patients with antiphospholipid syndrome (APS). In the absence of prospective, randomised trial data, reports of therapeutic failures in clinical practice alert clinicians to potential limitations of DOFI therapy for this indication. Data for all cases were collected from a centralised system that contains complete medical records of all patients treated and followed at Mayo Medical Center. We present here three consecutive APS patients who had had no thromboembolism recurrence on warfarin but were switched to DOFIs. The diagnosis of APS was established according to currently recommended criteria. The three cases were as follows: A woman with primary APS developed thrombotic endocarditis with symptomatic cerebral emboli after transition to dabigatran. A second woman with primary APS experienced ischemic arterial strokes and right transverse-sigmoid sinus thrombosis after conversion to rivaroxaban. A man with secondary APS suffered porto-mesenteric venous thrombosis after switching to rivaroxaban. None of these patients had failed warfarin prior to the transition to DOFIs. Based on these three cases, we advocate caution in using DOFIs for APS patients outside of a clinical trial setting, until further data becomes available.

Original languageEnglish (US)
Pages (from-to)947-950
Number of pages4
JournalThrombosis and Haemostasis
Volume112
Issue number5
DOIs
StatePublished - Jan 1 2014

Keywords

  • Antiphospholipid syndrome
  • Direct oral anticoagulants
  • Thromboembolic complications
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients'. Together they form a unique fingerprint.

  • Cite this